CX-13-608 / Ningbo Shengjian Biomedical Technology  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CX-13-608 / Ningbo Shengjian Biomedical Technology
ChiCTR1800017056: Phase I Clinical Trial of CX13-608 in the Treatment of Relapsed or Refractory Multiple Myeloma

Recruiting
1
56
 
iv infusion CX13-608
Renji Hospital Affiliated to Medical School, Shanghai Jiaotong University; Ning Bo SanJian BIoPharmaceuticals, Inc, Company funding & Government support
Relapsed or Refractory Multiple Myeloma
 
 

Download Options